Outcomes by Line of Therapy and Programmed Death Ligand 1 Expression in Patients With Advanced Melanoma Treated With Pembrolizumab or Ipilimumab in KEYNOTE-006: A Randomised Clinical Trial
European Journal of Cancer - United Kingdom
doi 10.1016/j.ejca.2018.06.034
Full Text
Open PDFAbstract
Available in full text
Date
September 1, 2018
Authors
Publisher
Elsevier BV